Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)

OBJECTIVE: GO-COLITIS aimed to measure the effectiveness of subcutaneous golimumab in tumour necrosis factor-α antagonist–naive patients with moderate to severe ulcerative colitis (UC) despite conventional treatment. DESIGN: GO-COLITIS was an open label, single arm, phase 4 study with a pragmatic de...

Descripción completa

Detalles Bibliográficos
Autores principales: Probert, Christopher SJ, Sebastian, Shaji, Gaya, Daniel R, Hamlin, P John, Gillespie, Gillian, Rose, Anita, Tate, Helen, Wheeler, Colin, Irving, Peter M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038835/
https://www.ncbi.nlm.nih.gov/pubmed/30002864
http://dx.doi.org/10.1136/bmjgast-2018-000212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038835/
https://www.ncbi.nlm.nih.gov/pubmed/30002864
http://dx.doi.org/10.1136/bmjgast-2018-000212

Ejemplares similares